.png){kind=icon}
.png){kind=icon}
Return
Clinical outcomes following switch from risankizumab to guselkumab in Crohn’s disease: a real-world case series
.png){kind=icon}
OA
AI
A
N
A
H
R
DOI：10.1093/ecco-jcc/jjag089.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Risankizumab is an interleukin (IL)-23 inhibitor that is effective for the treatment of moderate-to-severe Crohn’s disease (CD). However, many patients experience loss of response. Switching within the IL-23 inhibitor class to agents with more frequent dosing, such as guselkumab, may represent a salvage strategy, though no supporting data exist. We aimed to describe outcomes following switching between IL-23 antagonists.
Journal
IF:
8.7
Papers:
7.5K
Citations:
1.6W